Reducing thrombin formation during cardiopulmonary bypass: Is there a benefit of the additional anticoagulant action of aprotinin?

Journal of Cardiovascular Pharmacology

Volumn 27, Issue SUPPL. 1, 1996, Pages

  Dietrich, Wulf ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Aprotinin; Cardiopulmonary bypass; Coagulation; Contact phase activation; Fibrinolysis; Heparin

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN III; APROTININ; ARGATROBAN; BLOOD CLOTTING FACTOR 12; DESMOPRESSIN; FIBRIN; FIBRINOPEPTIDE A; HEPARIN; HIGH MOLECULAR WEIGHT KININOGEN; KALLIKREIN; PREKALLIKREIN; PROTHROMBIN; PROUROKINASE; SERINE PROTEINASE INHIBITOR; THROMBIN; TRANEXAMIC ACID;

CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG THERAPY; FIBRIN CLOT; FIBRINOLYSIS; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURGICAL RISK; THROMBOGENICITY;

EID: 0030060802     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199600001-00011     Document Type: Conference Paper

References (55)

1. Edmunds L Jr, Niewiarowski S, Colman RW. Invited letter concerning: aprotinin [Letter; Comment]. J Thorac Cardiovasc Surg 1991;101:1103-4.
2. Burman JF, Chung HI, Lane DA, Philippou H, Adami A, Lincoln JCR. Role of factor XII in thrombin generation and fibrinolysis during cardiopulmonary bypass. Lancet 1994;344: 1192-3.
3. Candio J, Prager D. Cardiopulmonary bypass and factor XII deficiency. Pennsylvania Med 1981;84:40.
4. Kelsey PR, Bottomley J, Grotte GJ, Maciver JE. Congenital factor XII deficiency: successful open heart surgery and anticoagulation. Clin Lab Haematol 1985;7:379-81.
5. Moorman RM, Reynolds DS, Comunale ME. Management of cardiopulmonary bypass in a patient with congenital factor XII deficiency. J Cardiothorac Vasc Anesth 1993;7:452-4.
6. Salmenpera M, Rasi V, Manila S. Cardiopulmonary bypass in a patient with factor XII deficiency. Anesthesiology 1991;75: 539-41.
7. Dietrich W, Spannagl M, Jochum M, et al. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization [Comment]. Anesthesiology 1990;73:1119-26.
8. Dietrich W, Spannagl M, Schramm W, Vogt W, Barankay A, Richter JA. The influence of preoperative anticoagulation on heparin response during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991;102:505-14.
9. Kurusz M, Wheeldon DR. Risk containment during cardiopulmonary bypass. Semin Thorac Cardiovasc Surg 1990;2: 400-9.
10. Beguin S, Hemker HC. Mode of action of enoxaparin in plasma. Acta Chir Scand 1990;556(suppl):51-6.
11. Hemker HC, Beguin S. Mode of action of unfractionated and low molecular weight heparins on the generation of thrombin in plasma. Haemostasis 1990;20(suppl 1):81-92.
12. Samama MM, Bara L, Gerotziafas GT. Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs). Haemostasis 1994;24:105-17.
13. 1 antitrypsin during cardiopulmonary bypass. Am J Clin Pathol 1983;80:459-64.
14. Pekna M, Hagman L, Halden E, Nilsson UR, Nilsson B, Thelin S. Complement activation during cardiopulmonary bypass: effects of immobilized heparin [Comment]. Ann Thorac Surg 1994;58:421-4.
15. Wagner WR, Johnson PC, Thompson KA, Marrone GC. Heparin-coated cardiopulmonary bypass circuits: hemostatic alterations and postoperative blood loss. Ann Thorac Surg 1994;58:734-40.
16. von Segesser LK, Weiss BM, Pasic M, Garcia E, Turina MI. Risk and benefit of low systemic heparinization during open heart operations [Comment]. Ann Thorac Surg 1994;58: 391-7.
17. Fosse E, Moen O, Johnson E, et al. Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass. Ann Thorac Surg 1994;58:472-7.
18. Cheung AT, Levin SK, Weiss SJ, Acker MA, Stenach N. Intracardiac thrombus: a risk of incomplete anticoagulation for cardiac operations [Comment]. Ann Thorac Surg 1994;58: 541-2.
19. Johnson PH. Hirudin: clinical potential of a thrombin inhibitor. Annu Rev Med 1994;45:165-77.
20. Gold HK, Torres FW, Garabedian HD, et al. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris [Comment]. J Am Coll Cardiol 1993;21: 1039-47.
21. Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs 1985;29:236-61.
22. Fritz H, Wunderer G. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittel-forschung 1983;33:479-94.
23. Kluft C, Dooijewaard G, Emeis JJ. Role of the contact system in fibrinolysis. Semin Thromb Hemost 1987;13:50-68.
24. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987;2:1289-91.
25. van Oeveren W, Jansen NJ, Bidstrup BP, et al. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg 1987;44:640-5.
26. Alajmo F, Calamai G, Perna A. High-dose aprotinin: hemostatic effects in open-heart operations. Ann Thorac Surg 1989;48:536-9.
27. Bidstrup BP, Royston D, Sapsford RN, Taylor KM. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 1989;97:364-72.
28. Blauhut B, Gross C, Necek S, Doran JE, Spath P, Lundsgaard-Hansen P. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass [Comment]. J Thorac Cardiovasc Surg 1991;101:958-67.
29. Dietrich W, Barankay A, Dilthey G, et al. Reduction of homologous blood requirements in cardiac surgery by intraoperative aprotinin application: clinical experience in 152 cardiac surgical patients. Thorac Cardiovasc Surg 1989;37:29-98.
30. Harder MP, Eijsman L, Roozendaal KJ, van Oeveren W, Wildevuur CR. Aprotinin reduces intraoperative and postoperative blood loss in membrane oxygenator cardiopulmonary bypass. Ann Thorac Surg 1991;51:936-41.
31. Havel M, Teufelsbauer H, Knobl P, et al. Effect of intraoperative aprotinin administration on postoperative bleeding in patients undergoing cardiopulmonary bypass operation. J Thorac Cardiovasc Surg 1991;101:968-72.
32. Lemmer J Jr, Stanford W, Bonney SL, et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg 1994;107:543-51.
33. van Oeveren W, Harder MP, Roozendaal KJ. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990;99:788-97.
34. Fraedrich G, Weber C, Bernard C, Hettwer A, Schlosser V. Reduction of blood transfusion requirement in open heart surgery by administration of high doses of aprotinin-preliminary results. Thorac Cardiovasc Surg 1989;37:89-91.
35. Murkin J, Lux J, Shannon N, et al. Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations. J Thorac Cardiovasc Surg 1994;107:554-61.
36. Cosgrove DMd, Heric B, Lytle BW, et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study [Comment]. Ann Thorac Surg 1992;54:1031-6.
37. Harker LA. Bleeding after cardiopulmonary bypass. N Engl J Med 1986;314:446-8.
38. Edmunds LH Jr. Blood platelets and bypass [Letter; Comment]. J Thorac Cardiovasc Surg 1989;97:470-1.
39. Ketterl R, Haas S, Lechner F, Kienzle H, Blumel G. Effect of aprotinin on thrombocytic function during total endoprosthesis surgery of the hip. Med Welt 1980;31:1239-43.
40. Ketterl R, Haas S, Heiss A, et al. Effect of the natural proteinase inhibitor aprotinin on platelet function in allo-arthroplastic hip replacement. Med Welt 1982;33:480-6.
41. Haas S, Ketterl R, Stemberger A, et al. The effect of aprotinin on platelet function, blood coagulation and blood lactate level in total hip replacement - a double blind clinical trial. Adv Exp Med Biol 1984;167:287-97.
42. Peerschke EI, Wainer JA. Examination of irreversible platelet-fibrinogen interactions. Am J Physiol 1985;248:C466-72.
43. Andersson TL, Solem JO, Tengborn L, Vinge E. Effects of desmopressin acetate on platelet aggregation, von Willebrand factor, and blood loss after cardiac surgery with extracorporeal circulation. Circulation 1990;81:872-8.
44. Lethagen S, Nilsson IM. DDAVP-induced enhancement of platelet retention: its dependence on platelet-von Willebrand factor and the platelet receptor GP IIb/IIIa. Eur J Haematol 1992;49:7-13.
45. Lu H, Soria C, Li H, et al. Role of active center and lysine binding sites of plasmin in plasmin-induced platelet activation and disaggregation. Thromb Haemost 1991;65:67-72.
46. Lu H, Soria C, Soria J, et al. Reversible translocation of glycoprotein Ib in plasmin-treated platelets: consequences for platelet function. Eur J Clin Invest 1993;23:785-93.
47. Lu H, Soria C, Commin PL, et al. Hemostasis in patients undergoing extracorporeal circulation: the effect of aprotinin (Trasylol). Thromb Haemost 1991;66:633-7.
48. Orchard MA, Goodchild CS, Prentice CR, et al. Aprotinin reduces cardiopulmonary bypass-induced blood loss and inhibits fibrinolysis without influencing platelets. Br J Haematol 1993;85:533-41.
49. Soslau G, Horrow J, Brodsky I. Effect of tranexamic acid on platelet ADP during extracorporeal circulation. Am J Hematol 1991;38:113-9.
50. Blauhut B, Harringer W, Bettelheim P, Doran JA, Späth P, Lundsgaard-Hansen P. Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1994;108: 1083-91.
51. Wachtfogel YT, Kucich U, Hack CE, et al. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 1993;106:1-9.
52. Dietrich W, Mendler N, Jochum M, Richter JA. Recombinant aprotinin (Arg 15 aprotinin) reduces hemostatic activation in simulated extracorporeal circulation [Abstract]. Anesthesiology 1993;79:A129.
53. Dilthey G, Dietrich W, Spannagl M, Jochum M. Coagulation patterns in cardiac patients with preoperative heparin treatment: the influence of high dose aprotinin [Abstract]. Proc Soc Cardiovasc Anesthesiol 1994;A231.
54. Marx G, Pokar H, Reuter H, Doering V, Tilsner V. The effects of aprotinin on hemostatic function during cardiac surgery. J Cardiothorac Vasc Anesth 1991;5:467-74.
55. Dietrich W, Spannagl M, Dooijewaard G, Richter JA. Protection of single-chain urokinase plasminogen activator (scuPA) by aprotinin in patients undergoing cardiopulmonary bypass (CPB) is due to contact phase inhibition [Abstract]. Anesthesiology 1994;81:A87.